Genmab — Januar 2024
-
Godmorgen
-
According to Cramer, health-care companies can yield bigger percentage gains than tech companies, for which investors should be looking. He also pointed out the large number of multibillion-dollar biopharma acquisitions announced at the end of 2023, saying investors should be on the lookout for more industry mergers.
9/1 2024 07:03 af Darvin
“Don’t forget that what we care about is percentage gains, not incremental gains,” he said. “And I think we can find bigger percentage gains in health care -
Tirsdagens danske avisuddrag med Vestas, Pandora og Genmab https://www.proinvestor.com/investornyt/1100847/tirsdagens-danske-avisuddrag-med-vestas-pandora-og-genmab
-
Kursmålet for Genmab sænkes med 14 pct. af canadisk finanshus https://www.proinvestor.com/investornyt/1100852/kursmalet-for-genmab-saenkes-med-14-pct-af-canadisk-finanshus
-
Novartis Strategy
& Growth Update
from
J.P. Morgan Healthcare Conference https://www.novartis.com/sites/novartis_com/files/2024-jpm-novartis-strategy-growth-update.pdf -
JPM24: As cancer players jump head-first into ADC field, Novartis CEO explains how he's resisted the temptation https://www.fiercepharma.com/pharma/jpm24-cancer-players-jump-head-first-adc-field-novartis-ceo-explains-how-hes-resisted
-
TIVDAK
(tisotumab vedotin-tftv) Supplemental Biologics License Application Accepted for Priority Review by U.S. Food and Drug https://www.proinvestor.com/investornyt/1100949/tivdak-tisotumab-vedotin-tftv-supplemental-biologics-license-application-accepted-for-priority-review-by-us-food-and-drug -
BioNTech Outlines 2024 Strategic Priorities at the 42nd Annual J.P. Morgan Healthcare Conference https://investors.biontech.de/news-releases/news-release-details/biontech-outlines-2024-strategic-priorities-42nd-annual-jp
-
"Based on emerging clinical data, the companies have planned engagement with health authorities on the design of a Phase 3 trial for BNT311/GEN1046 (acasunlimab) in second line NSCLC. The companies intend to share the data on which this decision was based at a medical conference in 2024."
-
Genmab tager skridt mod fuld godkendelse af middel mod livmoderhalskræft i USA https://www.proinvestor.com/investornyt/1100966/genmab-tager-skridt-mod-fuld-godkendelse-af-middel-mod-livmoderhalskraeft-i-usa
-
Godmorgen
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind